Zepbound pricing in 2026 — the real numbers
Zepbound is Eli Lilly’s FDA-approved indication for chronic weight management (the same tirzepatide molecule sold as Mounjaro for Type 2 diabetes). The 2026 list price is $1,060 per 4-pen monthly supply. Very few patients actually pay list — here are the paths that matter:
- LillyDirect self-pay vial: $349 (2.5mg), $499 (5mg–15mg). Single-dose vials shipped direct from Eli Lilly. The cheapest legal path for uninsured patients in 2026 and the benchmark every other option is measured against.
- Commercial insurance + Zepbound savings card: $25/month. If your plan covers Zepbound, covered copays drop to $25 (maximum benefit $469/month, ~$1,800 annual cap). Best path for insured patients for the first 3–4 fills of the year.
- Zepbound savings card without coverage: ~$591/month. A $469 off-list discount. Worse than LillyDirect vials for maintenance doses. Only useful if you specifically need pens rather than vials.
- Cash pay at pharmacy: $1,000–$1,080/month. GoodRx rarely helps with Zepbound. The only reason to go this path is if LillyDirect is temporarily out of stock on your specific dose.
- Compounded tirzepatide: $299–$449/month with individual necessity. The mass-market compounded path closed after the FDA shortage delisting. Regulatory risk is real.
Why LillyDirect changed the math
Before January 2024, a cash-pay Zepbound patient was looking at $1,000+/month at a retail pharmacy or $299/month from a compounding telehealth operation with questionable FDA standing. LillyDirect split the difference — $499/month for a pharmaceutical-grade branded product shipped to your door. Once the FDA delisted tirzepatide from its shortage list, most legitimate compounding for weight loss lost its legal basis, and LillyDirect became the default cash-pay choice.
The tradeoffs versus the branded pen:
- Single-dose vials— you draw each weekly dose with a syringe. Slightly less convenient than the pen’s click-dose mechanism but not difficult with 5 minutes of instruction.
- Cash-pay only— no insurance billing means no deductible credit. If you’re mid-deductible on an HDHP you would hit anyway, running Zepbound through insurance once is worth the math.
- HSA/FSA eligible — pay pre-tax and your effective cost drops 20–30% depending on your bracket.
- Dose-locked shipments — you order the specific dose you need each month. If your provider moves you down from 10mg to 7.5mg, you switch product codes on your next order.
The Zepbound savings card — when it actually wins
The Lilly savings card for Zepbound is unambiguously the best path for one scenario: commercial insurance that already covers Zepbound with a specialty-tier copay. Your first 3–4 fills land at $25/month. After the ~$1,800 annual cap, you pay full copay for the rest of the year (which on a $50–$300 tier looks reasonable). On a plan that covers Zepbound at a $25 copay without any card, you save nothing.
The savings card without coverage (~$591/month effective) is almost never the right choice — LillyDirect vials beat it by $92/month for the same molecule.
Zepbound OSA indication — Medicare coverage opened in 2025
In late 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity — the SURMOUNT-OSA indication. Medicare Part D began covering Zepbound for OSA in 2025, making Zepbound one of the only GLP-1s with a Medicare path for patients with obesity. Eligibility requires a documented AHI (apnea-hypopnea index) of 15+ events/hour on an in-lab or home sleep study. If you have both obesity and OSA and you’re on Medicare, pursuing this pathway through your prescriber is a materially different financial picture than trying to get Wegovy covered.
What a reasonable 2026 Zepbound budget looks like
Three realistic scenarios:
- Commercial insurance with AOM coverage: $25/month × first ~3 fills, then $50–$200/month for the rest of year one. Annual total: $600–$2,200.
- Uninsured or no AOM coverage, maintenance dose (5mg+): $499/month on LillyDirect × 12 = $5,988/year. HSA/FSA brings effective cost to ~$4,200–$4,700 depending on bracket.
- Medicare + OSA: $5–$50/month copay once approved, starting 2025. Annual total: $60–$600.
Plan for maintenance — tirzepatide is a chronic therapy. Stopping leads to regain (~50% of lost weight within 12 months per SURMOUNT-4 withdrawal data). Model 5-year totals before you commit.